# Refractory Chronic Cough FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/refractory-chronic-cough

> 4 upcoming FDA catalysts in refractory Chronic Cough: camlipixant (GSK) on Aug to Nov 2027 (topline data readout); camlipixant (GSK) on August 2027 (primary completion); nal er (TRVI) on September 2027 (primary completion); nal er (TRVI) on Sep to Dec 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug to Nov 2027 | [Camlipixant topline data readout](https://sec-api.dev/pdufa/camlipixant) | GSK | Refractory Chronic Cough | scheduled | "NCT07650084 (A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07650084)) |
| August 2027 | [Camlipixant primary completion](https://sec-api.dev/pdufa/camlipixant) | GSK | Refractory Chronic Cough | scheduled | "NCT07650084 (A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07650084)) |
| September 2027 | [Nal er primary completion](https://sec-api.dev/pdufa/nal-er) | TRVI | Refractory Chronic Cough | scheduled | "NCT07671924 (The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Trevi Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671924)) |
| Sep to Dec 2027 | [Nal er topline data readout](https://sec-api.dev/pdufa/nal-er) | TRVI | Refractory Chronic Cough | scheduled | "NCT07671924 (The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Trevi Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671924)) |

## Drugs

- [Camlipixant](https://sec-api.dev/pdufa/camlipixant) (GSK)
- [Nal er](https://sec-api.dev/pdufa/nal-er) (TRVI)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/refractory-chronic-cough.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Refractory Chronic Cough FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/refractory-chronic-cough

```bibtex
@misc{secapidev_indications_refractory_chronic_cough_20261116,
  title        = {Refractory Chronic Cough FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/refractory-chronic-cough}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_refractory_chronic_cough_20261116","title":"Refractory Chronic Cough FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/refractory-chronic-cough","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
